Exposure and response prevention versus risperidone for the treatment of tic disorders: a randomized controlled trial

IntroductionThe aim of this study was to directly compare behavior therapy (exposure & response prevention; ERP) with pharmacotherapy (risperidone) with respect to tic severity and quality of life in patients with Tourette's disorder or tic disorders.MethodA total of 30 participants wer...

Full description

Saved in:
Bibliographic Details
Main Authors: Jolande M. T. M. van de Griendt, Danielle C. Cath, Agnes A. A. C. M. Wertenbroek, Cara W. J. Verdellen, Judith J. G. Rath, Irene G. Klugkist, Sebastiaan F. T. M. de Bruijn, Marc J. P. M. Verbraak
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Psychiatry
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1360895/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850240655403515904
author Jolande M. T. M. van de Griendt
Jolande M. T. M. van de Griendt
Danielle C. Cath
Danielle C. Cath
Agnes A. A. C. M. Wertenbroek
Cara W. J. Verdellen
Judith J. G. Rath
Irene G. Klugkist
Sebastiaan F. T. M. de Bruijn
Marc J. P. M. Verbraak
Marc J. P. M. Verbraak
author_facet Jolande M. T. M. van de Griendt
Jolande M. T. M. van de Griendt
Danielle C. Cath
Danielle C. Cath
Agnes A. A. C. M. Wertenbroek
Cara W. J. Verdellen
Judith J. G. Rath
Irene G. Klugkist
Sebastiaan F. T. M. de Bruijn
Marc J. P. M. Verbraak
Marc J. P. M. Verbraak
author_sort Jolande M. T. M. van de Griendt
collection DOAJ
description IntroductionThe aim of this study was to directly compare behavior therapy (exposure & response prevention; ERP) with pharmacotherapy (risperidone) with respect to tic severity and quality of life in patients with Tourette's disorder or tic disorders.MethodA total of 30 participants were randomly assigned to either ERP (12 weekly 1-hour sessions) or risperidone (flexible dosage of 1-6 mg) with follow-up at 3 and 9 months after end of treatment. Outcome measures included tic severity as measured by the Yale Global Tic Severity Scale, quality of life and side effects. Predefined informative hypotheses were evaluated using Bayes factors (BF), a Bayesian alternative for null hypothesis testing with p-values, that provides a more reliable and powerful method in the case of small samples. A BF larger than one indicates support for the informative hypothesis and the larger the BF, the stronger the support, with a BF between 3 and 10 being considered to provide moderate evidence.ResultsBoth ERP and Risperidone were found to be effective with respect to tic severity at end of treatment (BF 5.35). At 9 months follow-up, results remained stable (BF 4.59), with an advantage of ERP over Risperidone at 3 months follow-up (BF 3.92). With respect to quality of life, an effect was found for ERP (BF 3.70 at 3 months follow up; BF 3.08 at 9 months follow-up). Dropout rates were higher in the medication condition, mainly due to significantly more side effects halfway during treatment, fading out towards end of treatment.DiscussionBehavior therapy and medication are equally viable options in the treatment of tic disorders, with a slight preference for ERP based on follow-up results on tic severity and quality of life, and side effects.Clinical trial registrationhttps://onderzoekmetmensen.nl/nl/node/23410/pdf, identifier NL-OMON23410.
format Article
id doaj-art-7efab28edecd4f16a9146feb98c1ce5a
institution OA Journals
issn 1664-0640
language English
publishDate 2025-03-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Psychiatry
spelling doaj-art-7efab28edecd4f16a9146feb98c1ce5a2025-08-20T02:00:47ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402025-03-011510.3389/fpsyt.2024.13608951360895Exposure and response prevention versus risperidone for the treatment of tic disorders: a randomized controlled trialJolande M. T. M. van de Griendt0Jolande M. T. M. van de Griendt1Danielle C. Cath2Danielle C. Cath3Agnes A. A. C. M. Wertenbroek4Cara W. J. Verdellen5Judith J. G. Rath6Irene G. Klugkist7Sebastiaan F. T. M. de Bruijn8Marc J. P. M. Verbraak9Marc J. P. M. Verbraak10Behavioural Science Institute, Radboud University Nijmegen, Nijmegen, NetherlandsTicXperts, Heteren, NetherlandsGeestelijke GezondheidsZorg Drenthe, Poliklinieken, Assen, NetherlandsDepartment of Psychiatry, University Medical Center Groningen (UMCG)/ Rijks Universiteit Groningen (RUG), Groningen, NetherlandsDepartment of Neurology, Ziekenhuis Groep Twente (ZGT), Hengelo, NetherlandsParnassia Group, PsyQ Nijmegen, Nijmegen, NetherlandsDepartment of Neurology, HAGA Hospital, The Hague, NetherlandsDepartment of Methodology and Statistics, Utrecht University, Utrecht, NetherlandsDepartment of Neurology, HAGA Hospital, The Hague, NetherlandsBehavioural Science Institute, Radboud University Nijmegen, Nijmegen, NetherlandsPro Persona Research, Pro Persona, Arnhem, NetherlandsIntroductionThe aim of this study was to directly compare behavior therapy (exposure & response prevention; ERP) with pharmacotherapy (risperidone) with respect to tic severity and quality of life in patients with Tourette's disorder or tic disorders.MethodA total of 30 participants were randomly assigned to either ERP (12 weekly 1-hour sessions) or risperidone (flexible dosage of 1-6 mg) with follow-up at 3 and 9 months after end of treatment. Outcome measures included tic severity as measured by the Yale Global Tic Severity Scale, quality of life and side effects. Predefined informative hypotheses were evaluated using Bayes factors (BF), a Bayesian alternative for null hypothesis testing with p-values, that provides a more reliable and powerful method in the case of small samples. A BF larger than one indicates support for the informative hypothesis and the larger the BF, the stronger the support, with a BF between 3 and 10 being considered to provide moderate evidence.ResultsBoth ERP and Risperidone were found to be effective with respect to tic severity at end of treatment (BF 5.35). At 9 months follow-up, results remained stable (BF 4.59), with an advantage of ERP over Risperidone at 3 months follow-up (BF 3.92). With respect to quality of life, an effect was found for ERP (BF 3.70 at 3 months follow up; BF 3.08 at 9 months follow-up). Dropout rates were higher in the medication condition, mainly due to significantly more side effects halfway during treatment, fading out towards end of treatment.DiscussionBehavior therapy and medication are equally viable options in the treatment of tic disorders, with a slight preference for ERP based on follow-up results on tic severity and quality of life, and side effects.Clinical trial registrationhttps://onderzoekmetmensen.nl/nl/node/23410/pdf, identifier NL-OMON23410.https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1360895/fullticsTourette’s disorderrisperidonebehavior therapyexposure and response prevention
spellingShingle Jolande M. T. M. van de Griendt
Jolande M. T. M. van de Griendt
Danielle C. Cath
Danielle C. Cath
Agnes A. A. C. M. Wertenbroek
Cara W. J. Verdellen
Judith J. G. Rath
Irene G. Klugkist
Sebastiaan F. T. M. de Bruijn
Marc J. P. M. Verbraak
Marc J. P. M. Verbraak
Exposure and response prevention versus risperidone for the treatment of tic disorders: a randomized controlled trial
Frontiers in Psychiatry
tics
Tourette’s disorder
risperidone
behavior therapy
exposure and response prevention
title Exposure and response prevention versus risperidone for the treatment of tic disorders: a randomized controlled trial
title_full Exposure and response prevention versus risperidone for the treatment of tic disorders: a randomized controlled trial
title_fullStr Exposure and response prevention versus risperidone for the treatment of tic disorders: a randomized controlled trial
title_full_unstemmed Exposure and response prevention versus risperidone for the treatment of tic disorders: a randomized controlled trial
title_short Exposure and response prevention versus risperidone for the treatment of tic disorders: a randomized controlled trial
title_sort exposure and response prevention versus risperidone for the treatment of tic disorders a randomized controlled trial
topic tics
Tourette’s disorder
risperidone
behavior therapy
exposure and response prevention
url https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1360895/full
work_keys_str_mv AT jolandemtmvandegriendt exposureandresponsepreventionversusrisperidoneforthetreatmentofticdisordersarandomizedcontrolledtrial
AT jolandemtmvandegriendt exposureandresponsepreventionversusrisperidoneforthetreatmentofticdisordersarandomizedcontrolledtrial
AT danielleccath exposureandresponsepreventionversusrisperidoneforthetreatmentofticdisordersarandomizedcontrolledtrial
AT danielleccath exposureandresponsepreventionversusrisperidoneforthetreatmentofticdisordersarandomizedcontrolledtrial
AT agnesaacmwertenbroek exposureandresponsepreventionversusrisperidoneforthetreatmentofticdisordersarandomizedcontrolledtrial
AT carawjverdellen exposureandresponsepreventionversusrisperidoneforthetreatmentofticdisordersarandomizedcontrolledtrial
AT judithjgrath exposureandresponsepreventionversusrisperidoneforthetreatmentofticdisordersarandomizedcontrolledtrial
AT irenegklugkist exposureandresponsepreventionversusrisperidoneforthetreatmentofticdisordersarandomizedcontrolledtrial
AT sebastiaanftmdebruijn exposureandresponsepreventionversusrisperidoneforthetreatmentofticdisordersarandomizedcontrolledtrial
AT marcjpmverbraak exposureandresponsepreventionversusrisperidoneforthetreatmentofticdisordersarandomizedcontrolledtrial
AT marcjpmverbraak exposureandresponsepreventionversusrisperidoneforthetreatmentofticdisordersarandomizedcontrolledtrial